-
公开(公告)号：US20190192535A1
公开(公告)日：2019-06-27
申请号：US16145768
申请日：2018-09-28
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Brian C. Shook , In Jong Kim , Thomas P. Blaisdell , Jianming Yu , Joseph Panarese , Kai Lin , Michael H.J. Rhodin , Nicole V. McAllister , Yat Sun Or
IPC: A61K31/5513 , A61P31/14
CPC classification number: A61K31/5513 , A61K31/4439 , A61K31/7056 , A61K39/395 , A61K39/42 , A61K45/06 , A61P31/14 , C07D213/12 , C07D213/14 , C07D217/12 , C07D217/14 , C07D243/24 , C07D403/12 , C07D491/04 , C07D498/08 , C07K16/1027 , C07K2317/24 , C07K2317/76 , A61K2300/00
Abstract: The present invention relates to pharmaceutical agents administered to a subject either in combination or in series for the treatment of a Respiratory Syncytial Virus (RSV) infection, wherein treatment comprises administering a compound effective to inhibit the function of the RSV and an additional compound or combinations of compounds having anti-RSV activity.
-
公开(公告)号：US20180237425A1
公开(公告)日：2018-08-23
申请号：US15898387
申请日：2018-02-16
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： In Jong Kim , Jianming Yu , Thomas P. Blaisdell , Joseph Panarese , Brian C. Shook , Yat Sun Or
IPC: C07D413/14
CPC classification number: C07D413/14
Abstract: The present invention relates to processes and intermediates useful in the preparation of biologically active molecules, especially in the synthesis of Respiratory Syncytial Virus (RSV) inhibitors. The present invention also relates to processes and intermediates for the preparation of compounds of formula (I): In particular, the present invention also relates to processes and intermediates for the preparation of compound I-a:
-
公开(公告)号：US09616099B2
公开(公告)日：2017-04-11
申请号：US14948876
申请日：2015-11-23
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Yat Sun Or , Guoqiang Wang , Jiang Long , In Jong Kim
CPC classification number: A61K38/13 , A61K38/00 , A61K38/21 , A61K45/06 , C07K7/645 , Y02A50/463 , A61K2300/00
Abstract: The present invention relates to novel cyclosporine analogs having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporine analog compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds.
-
公开(公告)号：US20160136233A1
公开(公告)日：2016-05-19
申请号：US14948876
申请日：2015-11-23
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Yat Sun Or , Guoqiang Wang , Jiang Long , In Jong Kim
CPC classification number: A61K38/13 , A61K38/00 , A61K38/21 , A61K45/06 , C07K7/645 , Y02A50/463 , A61K2300/00
Abstract: The present invention relates to novel cyclosporine analogues having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporine analogue compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds.
-
公开(公告)号：US08921573B2
公开(公告)日：2014-12-30
申请号：US14253976
申请日：2014-04-16
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Datong Tang , Guoyou Xu , Xiaowen Peng , Lu Ying , Ce Wang , Hui Cao , Jiang Long , In Jong Kim , Guoqiang Wang , Yao-Ling Qiu , Yat Sun Or
IPC: C07D403/14
CPC classification number: C07D403/14
Abstract: The present invention relates to processes and intermediates for the preparation of novel benzimidazole derivatives, especially in the synthesis of hepatitis C virus NS5A inhibitors. In particular, the present invention relates to processes and intermediates for the preparation of compounds of formulae (I-a):
Abstract translation: 本发明涉及制备新型苯并咪唑衍生物的方法和中间体，特别是在丙型肝炎病毒NS5A抑制剂的合成中。 特别地，本发明涉及制备式（I-a）化合物的方法和中间体：
-
Patent Agency Ranking
公开(公告)号：US20140316143A1
公开(公告)日：2014-10-23
申请号：US14253976
申请日：2014-04-16
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Datong Tang , Guoyou Xu , Xiaowen Peng , Lu Ying , Ce Wang , Hui Cao , Jiang Long , In Jong Kim , Guoqiang Wang , Yao-Ling Qiu , Yat Sun Or
IPC: C07D403/14
CPC classification number: C07D403/14
Abstract: The present invention relates to processes and intermediates for the preparation of novel benzimidazole derivatives, especially in the synthesis of hepatitis C virus NS5A inhibitors. In particular, the present invention relates to processes and intermediates for the preparation of compounds of formulae (I-a):
Abstract translation: 本发明涉及制备新型苯并咪唑衍生物的方法和中间体，特别是在丙型肝炎病毒NS5A抑制剂的合成中。 特别地，本发明涉及制备式（I-a）化合物的方法和中间体：
-
37.发明申请PROCESSES FOR THE PREPARATION OF 2-FLUORO 6-11 BICYCLIC ERYTHROMYCIN DERIVATIVES 审中-公开制备2-氟六氨基二硫代吗啉衍生物的方法公开(公告)号：US20140073797A1
公开(公告)日：2014-03-13
申请号：US14019604
申请日：2013-09-06
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Guoyou Xu , Datong Tang , In Jong Kim , Ly Tam Phan , Yat Sun Or , Zhe Wang
IPC: C07D417/04
CPC classification number: C07D417/04 , C07D417/14 , C07D493/08
Abstract: The present invention relates to processes and intermediates for the preparation of 2-fluoro 6-11 bicyclic erythromycin derivatives. In particular, the present invention relates to processes and intermediates for the preparation of a compound of formula (X-c):
Abstract translation: 本发明涉及制备2-氟6-11双环红霉素衍生物的方法和中间体。 特别地，本发明涉及制备式（X-c）化合物的方法和中间体：
-
公开(公告)号：US12006326B2
公开(公告)日：2024-06-11
申请号：US17894412
申请日：2022-08-24
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Adam Szymaniak , Kevin McGrath , Jianming Yu , Tyler Mann , Long Nguyen , Kaicheng Zhu , In Jong Kim , Yat Sun Or
IPC: C07D491/052 , C07D471/04 , C07D491/044 , C07D491/048
CPC classification number: C07D491/052 , C07D471/04 , C07D491/044 , C07D491/048
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:
which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.-
公开(公告)号：US11952389B2
公开(公告)日：2024-04-09
申请号：US17735258
申请日：2022-05-03
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Brian C. Shook , In Jong Kim , Thomas P. Blaisdell , Jianming Yu , Joseph D. Panarese , Yat Sun Or
IPC: C07D235/24 , A61K31/5513 , A61K31/56 , A61K31/58 , A61K45/06 , A61P31/14 , A61P31/16 , C07D243/16 , C07D403/12 , C07D413/12 , C07D413/14 , C07D417/14 , C07D471/08 , C07D491/048 , C07D495/04 , C07D498/08 , C07D513/04
CPC classification number: C07D513/04 , A61K31/5513 , A61K31/56 , A61K31/58 , A61K45/06 , C07D243/16 , C07D413/12 , C07D413/14 , C07D417/14 , C07D471/08 , C07D491/048 , C07D495/04 , C07D498/08 , A61K31/5513 , A61K2300/00 , A61K31/58 , A61K2300/00 , A61K31/56 , A61K2300/00
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:
which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.-
公开(公告)号：US11945824B2
公开(公告)日：2024-04-02
申请号：US17503626
申请日：2021-10-18
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Yat Sun Or , Yong He , Kevin McGrath , Ruichao Shen , Adam Szymaniak , Xuechao Xing , In Jong Kim , Guoqiang Wang
IPC: A61K31/706 , A61K31/635 , A61K45/06 , A61P31/14 , A61P35/00 , C07D491/048
CPC classification number: C07D491/048 , A61K45/06 , A61P31/14
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:
which inhibit Respiratory Syncytial Virus (RSV) or HMPV. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV or HMPV infection. The invention also relates to methods of treating an RSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
-
-
-
-
-
-
-
-
-
Search Results
68
records
(took 0.034 seconds)
